Keywords: comparative, study, call, zofran, glaxo, 5-ht3, receptor
COMPARATIVE STUDY CALL WITH ZOFRAN
Article | 23 March 1992
Glaxo's 5-HT3 receptor antagonist anti-emetic Zofran (ondansetron) represents a great improvement on earlier anti-emetics for chemotherapy regimens that include cisplatin, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
